Prognostic Significance of Neurofilament light in Fingolimod therapy for Multiple Sclerosis: A Systemic Review and Meta-Analysis based on Randomized Control Trials

Published:November 16, 2022DOI:


      • Quantitative analysis which showed increased NfL was related to significant increase in cognitive disability worsening (HR= 1.40 [1.25, 1.58]; p< 0.00001; I2= 17%).
      • There was significant decrease in NfL levels when Fingolimod was used as compared to placebo.
      • Increasing NfL levels are associated with increased incidence of relapses, active/new T2 lesions and increased percentage of brain volume change.
      • NfL is considered as a potential biomarker for MS prognosis and disease progression monitoring.



      : This research was conducted to assess Neurofilament light chain (NfL) as prognostic factor for Multiple Sclerosis and effect of Fingolimod on plasma levels of NfL.

      Materials and Methods

      : A systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 7th September 2022. All statistical analyses were conducted in Review Manager 5.4.1. Studies meeting inclusion criteria were selected. Only those studies that involved Multiple sclerosis patients in which plasma levels of NfL was provided and Fingolimod was used in the treatment group. Fixed-effect model was used to pool the studies to assess NfL as prognostic factor, which was reported in the Hazards ratio (HR) and their corresponding 95% confidence interval (CI). Moreover, effect of Fingolimod on NfL levels was analysed qualitatively.


      : Five Randomized Controlled Trials were used in the study. Four studies were used in quantitative analysis which showed increased NfL was related to significant increase in cognitive disability worsening (HR= 1.66 [1.35, 2.05]; p< 0.00001; I2= 0%). The qualitative analysis method was employed to evaluate the factors correlating with increased NfL levels in Multiple Sclerosis patients. Five studies evaluated that there was significant decrease in NfL levels when Fingolimod was used as compared to placebo. 4 studies were included to correlated NfL levels with clinical and MRI parameters and association was found between increasing NfL levels and relapses, active/new T2 lesions and percentage of brain volume change.


      : The results of our meta-analysis and systematic review demonstrated statistically significant effect of NfL as a prognostic marker with its level being decreased significantly when Fingolimod was used for treating Multiple Sclerosis


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Oh J
        • Vidal-Jordana A
        • Montalban X.
        Multiple sclerosis: clinical aspects.
        Curr Opin Neurol. 2018; 31: 752-759
        • Compston A
        • Coles A.
        Multiple sclerosis.
        Lancet. 2008; 372: 1502-1517
        • Leray E
        • Moreau T
        • Fromont A
        • Edan G.
        Epidemiology of multiple sclerosis.
        Rev Neurol (Paris). 2016; 172: 3-13
        • Katz Sand I.
        Classification, diagnosis, and differential diagnosis of multiple sclerosis.
        Curr Opin Neurol. 2015; 28: 193-205
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • Correale J.
        • Fazekas F.
        • Filippi M.
        • Freedman M.S.
        • Fujihara K.
        • Galetta S.L.
        • Hartung H.P.
        • Kappos L.
        • Lublin F.D.
        • Marrie R.A.
        • Miller A.E.
        • Miller D.H.
        • Montalban X.
        • Mowry E.M.
        • Cohen J.A.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        The Lancet. Neurology. 2018; 17: 162-173
        • Håkansson I
        • Tisell A
        • Cassel P
        • et al.
        Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
        Eur J Neurol. 2017; 24: 703-712
        • Martin SJ
        • McGlasson S
        • Hunt D
        • Overell J.
        Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
        J Neurol Neurosurg Psychiatry. 2019; 90: 1059-1067
        • Chun J
        • Kihara Y
        • Jonnalagadda D
        • Blaho VA.
        Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
        Annu Rev Pharmacol Toxicol. 2019; 59: 149-170
        • Liu N
        • Sun M
        • Zhang W
        • et al.
        Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
        J Clin Neurosci. 2022; 101: 198-203
        • Ragonese P
        • Aridon P
        • Salemi G
        • D'Amelio M
        • Savettieri G
        Mortality in multiple sclerosis: a review.
        Eur J Neurol. 2008; 15: 123-127
        • Hutton B
        • Salanti G
        • Caldwell DM
        • et al.
        The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
        Ann Intern Med. 2015; 162: 777-784
        • Hartmann KE
        • Jerome RN
        • Lindegren ML
        • et al.
        Primary Care Management of Abnormal Uterine Bleeding.
        Rockville (MD): Agency for Healthcare Research and Quality, US2013 Mar ([Internet](Comparative Effectiveness Reviews, No. 96.) Appendix F, Cochrane Risk of Bias Tool. Available from)
        • Cumpston M
        • Li T
        • Page MJ
        • et al.
        Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.
        Cochrane Database Syst Rev. 2019; 10ED000142
        • Kuhle J
        • Disanto G
        • Lorscheider J
        • et al.
        Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
        Neurology. 2015; 84: 1639-1643
        • Sormani MP
        • Haering DA
        • Kropshofer H
        • et al.
        Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.
        Ann Clin Transl Neurol. 2019; 6 (Published 2019 May 28): 1081-1089
        • Kuhle J
        • Kropshofer H
        • Haering DA
        • et al.
        Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
        Neurology. 2019; 92: e1007-e1015
        • Häring DA
        • Kropshofer H
        • Kappos L
        • et al.
        Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
        Neurol Neuroimmunol Neuroinflamm. 2020; 7 (Published 2020 Aug 12): e856
        • Leppert D
        • Kropshofer H
        • Häring DA
        • et al.
        Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
        Neurology. 2022; 98: e2120-e2131
        • Bittner S
        • Oh J
        • Havrdová EK
        • Tintoré M
        • Zipp F.
        The potential of serum neurofilament as biomarker for multiple sclerosis.
        Brain. 2021; 144: 2954-2963
        • Zipp F
        • Oh J
        • Fragoso YD
        • Waubant E.
        Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis.
        Nat Rev Neurol. 2019; 15: 441-445
        • Irfan SA
        • Murtaza M
        • Ahmed A
        • et al.
        Promising role of temelimab in multiple sclerosis treatment.
        Mult Scler Relat Disord. 2022; 61103743